mosunetuzumab,Atezolizumab
roche
['follicular', 'lymphoma', 'mosunetuzumab', 'lymsm']
congress #eha2023 | laurie sehn presents a phase ii study of mosunetuzumab in pts with r/r follicular #lymphoma. n=90. 60% achieved cr as best response: 54% achieved cr at eot; 1 pt with a cr experienced pd in c8; &amp; 4 pts achieved cr after eot. #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm